New Technology for Accelerating Development of Vaccines Against H5N1 Flu Enters Pilot Study at ProImmune
ProImmune has developed REVEAL & ProVE(TM), a novel technology that enables scientists to identify the specific antigens on viruses that can be detected by the immune system and used as targets in vaccine development. The new screening system enables researchers to analyse any protein derived from a pathogen for potential immunogenicity within only four weeks, a process that has previously taken many months to complete. The pilot study will explore the protein sequence of the key H5 protein in the avian influenza virus.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.